World's Only Research Centre On Mycetoma Destroyed In Sudan War
Cairo:
The world's only research centre on mycetoma, a neglected tropical disease common among farmers, has been destroyed in Sudan's two-year war, its director and another expert say.
Mycetoma is caused by bacteria or fungus and usually enters the body through cuts. It is a progressively destructive infectious disease of the body tissue, affecting skin, muscle and even bone.
It is often characterised by swollen feet, but can also cause barnacle-like growths and club-like hands.
"The centre and all its infrastructure were destroyed during the war in Sudan," Ahmed Fahal, director of the Mycetoma Research Centre (MRC), told AFP.
"We lost the entire contents of our biological banks, where there was data from more than 40 years," said Fahal, whose centre had treated thousands of patients from Sudan and other countries.
"It's difficult to bear."
Since April 15, 2023, Sudan's army has been at war with the paramilitary Rapid Support Forces throughout the northeast African country.
The MRC is located in the Khartoum area, which the army last month reclaimed from the RSF during a war that has killed tens of thousands of people and uprooted more than 12 million.
Sudan's health care system has been left at the "breaking point", according to the World Health Organization.
Among the conflict's casualties is now the MRC, established in 1991 under the auspices of the University of Khartoum. It was a rare story of medical success in impoverished Sudan.
A video provided by the global Drugs for Neglected Diseases initiative (DNDi) shows collapsed ceilings, shelves overturned, fridges open and documents scattered about.
AFP was not able to independently verify the MRC's current condition.
The centre had grown to include 50 researchers and treat 12,000 patients each year, Fahal said.
Mycetoma is listed as a neglected tropical disease by the WHO.
The organisms that cause mycetoma also occur in Sudan's neighbours, including Chad and Ethiopia, as well as in other tropical and sub-tropical areas, among them Mexico and Thailand, WHO says.
For herders, farmers and other workers depending on manual labour to survive, crippling mycetoma infections can be a life sentence.
Drawing on the MRC's expertise, in 2019 the WHO and Sudan's government convened the First International Training Workshop on Mycetoma, in Khartoum.
"Today, Sudan, which was at the forefront of awareness of mycetomas, has gone 100 percent backwards," said Dr. Borna Nyaoke-Anoke, DNDi's head of mycetoma.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
9 hours ago
- Time of India
What is RSV and why are infants especially at risk in India?
Respiratory Syncytial Virus, commonly known as RSV, is the leading cause of respiratory illness in children and infants worldwide. In India, RSV has also become a major issue for parents as well as pediatricians, particularly in the post-monsoon and winter seasons when cases surge. Although the nation continues to establish complete surveillance information, existing studies in tertiary care facilities show that RSV contributes 30% to 50% of bronchiolitis and pneumonia incidents in children aged two years and below. RSV is usually responsible for the symptoms of a cold in older children and adults. Nevertheless, in infants—especially those under six months of age, those who were premature at birth, or those with underlying health issues—the virus may cause severe lower respiratory tract infections, including bronchiolitis (inflammation of small airways) and pneumonia. These two diseases usually require hospitalization, and hospitalization rates between 3 and 5 per 100 infants less than one year of age per year have been estimated in India. The risks are not equal throughout the nation. Geographic and socioeconomic variations account for both the risk of and outcome of RSV infection. Children living in lower-income populations or in densely populated urban environments can have increased exposure from lesser access to healthcare, suboptimal ventilation, and slower diagnosis. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Eat 1 Teaspoon Every Night, See What Happens A Week Later [Video] getfittoday Undo Seeing the international burden of RSV, the World Health Organization (WHO) recently supported maternal RSV vaccination as a prevention approach. This entails immunizing pregnant women so that antibodies are passed on to the unborn child, providing immunity in the vulnerable early months of life. Although not yet included in India's Universal Immunization Programme (UIP), Indian health authorities, such as the Indian Academy of Pediatrics, are in the process of evaluating the vaccine's safety, effectiveness, and affordability in India. Phased introduction in high-risk groups could be the initial step. Apart from vaccines, monoclonal antibodies too have been promising in the prevention of RSV-related complications. These provide passive immunity in a single dose of injection. But the big constraint is cost. Without government incentives or being covered under public health schemes, these therapies could prove to be out of reach for the majority of Indian families. Differential pricing models and collaborations with insurance companies will become paramount in order to expand access. More encouragingly, Indian drug makers are not idle either. Bharat Biotech and Serum Institute of India have initiated RSV research programs and are likely to bank on their experience in the production of pediatric and maternal vaccines. Tie-ups with global firms can also open the way for local production of monoclonal antibodies, leading to costs savings as well as wider availability. Experts put wide availability of RSV vaccines and antibodies in India at least 2 to 4 years down the road. Early access could start in corporate or private hospitals dealing with high-risk pregnancies. In the private sector, however, the incorporation of RSV prevention in the national immunization program will be crucial to making RSV vaccines and antibodies accessible and beneficial for all Indian infants—irrespective of birthplace. Article courtesy: Dr. Shreya Dubey - Consultant - Neonatology & Paediatrics, CK Birla Hospital, Gurugram Russia's Lavrov Sounds Alarm Over German Army Buildup Plan; 'Very Worrying, Need To…' One step to a healthier you—join Times Health+ Yoga and feel the change
&w=3840&q=100)
Business Standard
10 hours ago
- Business Standard
India recorded 8.6 mn deaths in 2022, down 15% from Covid peak: CRS data
India saw over 8.6 million registered deaths in 2022, marking a drop of more than 15 per cent compared to the 10.2 million deaths recorded in 2021, according to data from the Civil Registration System (CRS). This decline of 1.5 million deaths brought the country's mortality figures back in line with levels seen before the Covid-19 pandemic. The CRS report, released by the Office of the Registrar General of India and accessed by the Press Trust of India, highlighted the abnormal rise in deaths during 2021, when the second wave of the pandemic took a severe toll. In contrast, deaths in 2020 were 8.1 million, in 2019 they stood at 7.6 million, and in 2018, 6.9 million. 'In the case of registered deaths, the number has decreased from 10.2 million in 2021 to 8.6 million in 2022, i.e. a decrease of 15.4 per cent. Some of the major states, namely, Gujarat, Maharashtra, Madhya Pradesh, Andhra Pradesh, Tamil Nadu, Uttar Pradesh, Karnataka, West Bengal, Bihar and Haryana have contributed significantly to the decreased number of registered deaths,' the report stated. Government challenges WHO's Covid estimates As of July 26, 2022, the Indian government reported 526,000 deaths due to Covid-19. However, the World Health Organisation had estimated over 4.7 million Covid-linked deaths in India, a claim that was firmly rejected by the Indian government. 'India had registered a strong objection to the process, methodology and outcome of this unscientific modelling approach especially when India had provided authentic data published through the Civil Registration System by Registrar General of India to WHO,' the government stated in a response in the Lok Sabha on July 29, 2022. Rise in registered births in 2022 The CRS report also revealed that over 25.4 million births were registered in 2022 — an increase from 24.2 million in 2021, reflecting a growth of about 5.1 per cent. 'The number of registered births has increased from 24.2 million in 2021 to 25.4 million in 2022,' the report said. Nearly all states and Union Territories saw an increase in birth registrations, except for Bihar, Haryana, Himachal Pradesh, Sikkim, West Bengal, Ladakh, and Lakshadweep. 'Nine major states, namely Uttar Pradesh, Madhya Pradesh, Maharashtra, Jharkhand, Karnataka, Gujarat, Telangana, Chhattisgarh and Assam have contributed significantly to the increase in registered births in 2022 over 2021,' the report added. 'On the other hand, a decrease in registered births in six figures has been observed in two major states, namely West Bengal and Bihar during 2021-2022,' it said.
Hindustan Times
10 hours ago
- Hindustan Times
Health Talk: WHO flags RSV deaths in children, calls for new immunisation tools
The World Health Organisation (WHO) recently issued recommendations, including the effective use of immunisation products, to protect infants against Respiratory Syncytial Virus (RSV), which causes acute lower respiratory infections in children and can become life-threatening. RSV, one of the leading causes of under-five mortality globally (which refers to the death of children before their fifth birthday, typically expressed as a rate per 1,000 live births), is responsible for around 1 lakh deaths and over 3.6 million hospitalisations in children under the age of five every year, according to the United Nation health body. About half of these deaths occur in infants younger than six months of age. The vast majority (97%) of RSV deaths in infants occur in low- and middle-income countries, where there is limited access to supportive medical care such as oxygen or hydration. India also has a high disease burden, particularly around the rainy season. A 'position paper' published by WHO outlines recommendations for two immunisation products — a maternal vaccine that can be given to pregnant women in their third trimester to protect their infant, and a long-acting monoclonal antibody that can be administered to infants from birth, just before or during the RSV season. 'RSV is an incredibly infectious virus that infects people of all ages, but is especially harmful to infants, particularly those born premature, when they are most vulnerable to severe disease,' director of immunization, vaccines, and biologicals at WHO Kate O'Brien said in a statement. 'The WHO-recommended RSV immunisation products can transform the fight against severe RSV disease, dramatically reduce hospitalizations, and deaths, ultimately saving many infant lives globally,' he added. A 2021 study — Disease Burden Due to Respiratory Syncytial Virus in Indian Pediatric Population: A Literature Review — said, 'In India, epidemiology of RSV infection is well documented in young children (0-5 years) as compared to children from other age groups. The rates of RSV detection in various studies conducted in younger children (0-5 years) vary from 2.1% to 62.4% in India which is higher as compared to children from other age groups.' RSV usually causes mild symptoms similar to the common cold, including runny nose, cough, and fever. However, it can lead to serious complications — including pneumonia and bronchiolitis — in infants, young children, older adults, and those with compromised immune systems or underlying health conditions. Better management and putting in place preventive measures is largely the key to stopping any disease from turning big. The WHO recommendations will hopefully serve the purpose, and the world will see fewer deaths in children due to RSV.
